EXHIBIT 1

POWER OF ATTORNEY

We, the undersigned, under the authority granted to each of us to sign jointly on behalf of Novartis AG, hereby grant powers to Bart Dzikowski, Anja Koenig, Florian Muellershausen, Marianne Uteng, Mathias Frederiksen, Beat Steffen and Helena Sanchez, and constitute and appoint any two of them jointly as our true and lawful attorneys and representatives and to act on our behalf and to sign filings to be made with the U.S. Securities and Exchange Commission (the “SEC”) relating to the shares of Oculis S.A. and its successor companies held by Novartis Bioventures Ltd., an indirect subsidiary of Novartis AG, as required by the SEC (the “SEC Filings”), and to undertake and carry out all tasks and formalities on our behalf which may be required in connection with giving effect to the SEC Filings.

We, the undersigned, undertake to ratify and confirm whatever our true and lawful attorneys do or purport to do in good faith in the exercise of any power conferred by this Power of Attorney.

We, the undersigned, declare that a person who deals with our true and lawful attorneys in good faith may accept a written statement signed by such attorneys to the effect that this Power of Attorney has not been revoked as conclusive evidence of that fact.

The authority granted by this Power of Attorney shall expire immediately after the SEC Filings are no longer required.

IN WITNESS WHEREOF, this Power of Attorney is duly signed on this 18 day of October 2022.

Novartis AG

/s/ L. Förtsch

Name: Lukas Förtsch

Title: Authorized Signatory

/s/ C. Rehm

Name: Christian Rehm

Title: Authorized Signatory

POWER OF ATTORNEY

We, the undersigned, under the authority granted to each of us to sign jointly on behalf of Novartis Pharma AG, hereby grant powers to Bart Dzikowski, Marc Ceulemans, Anja Koenig, Florian Muellershausen, Marianne Uteng, Mathias Frederiksen, Beat Steffen and Helena Sanchez, and constitute and appoint any two of them jointly as our true and lawful attorneys and representatives and to act on our behalf and to sign filings to be made with the U.S. Securities and Exchange Commission (the “SEC”) relating to the shares of Oculis S.A. and its successor companies held by Novartis Pharma AG, as required by the SEC (the “SEC Filings”), and to undertake and carry out all tasks and formalities on our behalf which may be required in connection with giving effect to the SEC Filings.

We, the undersigned, undertake to ratify and confirm whatever our true and lawful attorneys do or purport to do in good faith in the exercise of any power conferred by this Power of Attorney.

We, the undersigned, declare that a person who deals with our true and lawful attorneys in good faith may accept a written statement signed by such attorneys to the effect that this Power of Attorney has not been revoked as conclusive evidence of that fact.

The authority granted by this Power of Attorney shall expire immediately after the SEC Filings are no longer required.

IN WITNESS WHEREOF, this Power of Attorney is duly signed on this 3 day of November 2022.

Novartis AG

/s/ L. Förtsch

Name: Lukas Förtsch

Title: Authorized Signatory

/s/ B. Bugnon

Name: Bertrand Bugnon

Title: Authorized Signatory